Selected research
Industry Research
Endometriosis Drugs Industry Research Report 2026
Market perspective
The global Endometriosis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Endometriosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Endometriosis Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Endometriosis Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Endometriosis Drugs include Takeda Pharmaceutical Company, Pfizer, AbbVie, AstraZeneca, ValiRx, Roivant Sciences, Repros Therapeutics, ObsEva and Neurocrine Biosciences, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Endometriosis Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Endometriosis Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Endometriosis Drugs Market by Company
Takeda Pharmaceutical Company
Pfizer
AbbVie
AstraZeneca
ValiRx
Roivant Sciences
Repros Therapeutics
ObsEva
Neurocrine Biosciences
Kissei Pharmaceutical
Evotec
Debiopharm Group
Astellas Pharma
Endometriosis Drugs Segment by Type
Chinese Herbs
Progestogens
Hormonal Therapy
Add-back Medication
Endometriosis Drugs Segment by Application
Research Institutes
Hospitals
Clinics
Endometriosis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Endometriosis Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chinese Herbs
- Progestogens
- Hormonal Therapy
- Add-back Medication
Applications
- Research Institutes
- Hospitals
- Clinics
Companies covered
- Takeda Pharmaceutical Company
- Pfizer
- AbbVie
- AstraZeneca
- ValiRx
- Roivant Sciences
- Repros Therapeutics
- ObsEva
- Neurocrine Biosciences
- Kissei Pharmaceutical
- Evotec
- Debiopharm Group
- Astellas Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Endometriosis Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Chinese Herbs
- 2.2.3 Progestogens
- 2.2.4 Hormonal Therapy
- 2.2.5 Add-back Medication
- 2.3 Endometriosis Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Research Institutes
- 2.3.3 Hospitals
- 2.3.4 Clinics
- 2.4 Assumptions and Limitations
3 Endometriosis Drugs Breakdown Data by Type
- 3.1 Global Endometriosis Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Endometriosis Drugs Forecasted Market Size by Type (2027-2032)
4 Endometriosis Drugs Breakdown Data by Application
- 4.1 Global Endometriosis Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Endometriosis Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Endometriosis Drugs Market Perspective (2021-2032)
- 5.2 Global Endometriosis Drugs Growth Trends by Region
- 5.2.1 Global Endometriosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Endometriosis Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Endometriosis Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Endometriosis Drugs Market Dynamics
- 5.3.1 Endometriosis Drugs Industry Trends
- 5.3.2 Endometriosis Drugs Market Drivers
- 5.3.3 Endometriosis Drugs Market Challenges
- 5.3.4 Endometriosis Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Endometriosis Drugs Players by Revenue
- 6.1.1 Global Top Endometriosis Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Endometriosis Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Endometriosis Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Endometriosis Drugs Head Office and Area Served
- 6.4 Global Endometriosis Drugs Players, Product Type & Application
- 6.5 Global Endometriosis Drugs Manufacturers Established Date
- 6.6 Global Endometriosis Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Endometriosis Drugs Market Size (2021-2032)
- 7.2 North America Endometriosis Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Endometriosis Drugs Market Size by Country (2021-2026)
- 7.4 North America Endometriosis Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Endometriosis Drugs Market Size (2021-2032)
- 8.2 Europe Endometriosis Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Endometriosis Drugs Market Size by Country (2021-2026)
- 8.4 Europe Endometriosis Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Endometriosis Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Endometriosis Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Endometriosis Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Endometriosis Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Endometriosis Drugs Market Size (2021-2032)
- 10.2 South America Endometriosis Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Endometriosis Drugs Market Size by Country (2021-2026)
- 10.4 South America Endometriosis Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Endometriosis Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Endometriosis Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Endometriosis Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Endometriosis Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda Pharmaceutical Company
- 12.1.1 Takeda Pharmaceutical Company Company Information
- 12.1.2 Takeda Pharmaceutical Company Business Overview
- 12.1.3 Takeda Pharmaceutical Company Revenue in Endometriosis Drugs Business (2021-2026)
- 12.1.4 Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio
- 12.1.5 Takeda Pharmaceutical Company Recent Developments
- 12.2 Pfizer
- 12.2.1 Pfizer Company Information
- 12.2.2 Pfizer Business Overview
- 12.2.3 Pfizer Revenue in Endometriosis Drugs Business (2021-2026)
- 12.2.4 Pfizer Endometriosis Drugs Product Portfolio
- 12.2.5 Pfizer Recent Developments
- 12.3 AbbVie
- 12.3.1 AbbVie Company Information
- 12.3.2 AbbVie Business Overview
- 12.3.3 AbbVie Revenue in Endometriosis Drugs Business (2021-2026)
- 12.3.4 AbbVie Endometriosis Drugs Product Portfolio
- 12.3.5 AbbVie Recent Developments
- 12.4 AstraZeneca
- 12.4.1 AstraZeneca Company Information
- 12.4.2 AstraZeneca Business Overview
- 12.4.3 AstraZeneca Revenue in Endometriosis Drugs Business (2021-2026)
- 12.4.4 AstraZeneca Endometriosis Drugs Product Portfolio
- 12.4.5 AstraZeneca Recent Developments
- 12.5 ValiRx
- 12.5.1 ValiRx Company Information
- 12.5.2 ValiRx Business Overview
- 12.5.3 ValiRx Revenue in Endometriosis Drugs Business (2021-2026)
- 12.5.4 ValiRx Endometriosis Drugs Product Portfolio
- 12.5.5 ValiRx Recent Developments
- 12.6 Roivant Sciences
- 12.6.1 Roivant Sciences Company Information
- 12.6.2 Roivant Sciences Business Overview
- 12.6.3 Roivant Sciences Revenue in Endometriosis Drugs Business (2021-2026)
- 12.6.4 Roivant Sciences Endometriosis Drugs Product Portfolio
- 12.6.5 Roivant Sciences Recent Developments
- 12.7 Repros Therapeutics
- 12.7.1 Repros Therapeutics Company Information
- 12.7.2 Repros Therapeutics Business Overview
- 12.7.3 Repros Therapeutics Revenue in Endometriosis Drugs Business (2021-2026)
- 12.7.4 Repros Therapeutics Endometriosis Drugs Product Portfolio
- 12.7.5 Repros Therapeutics Recent Developments
- 12.8 ObsEva
- 12.8.1 ObsEva Company Information
- 12.8.2 ObsEva Business Overview
- 12.8.3 ObsEva Revenue in Endometriosis Drugs Business (2021-2026)
- 12.8.4 ObsEva Endometriosis Drugs Product Portfolio
- 12.8.5 ObsEva Recent Developments
- 12.9 Neurocrine Biosciences
- 12.9.1 Neurocrine Biosciences Company Information
- 12.9.2 Neurocrine Biosciences Business Overview
- 12.9.3 Neurocrine Biosciences Revenue in Endometriosis Drugs Business (2021-2026)
- 12.9.4 Neurocrine Biosciences Endometriosis Drugs Product Portfolio
- 12.9.5 Neurocrine Biosciences Recent Developments
- 12.10 Kissei Pharmaceutical
- 12.10.1 Kissei Pharmaceutical Company Information
- 12.10.2 Kissei Pharmaceutical Business Overview
- 12.10.3 Kissei Pharmaceutical Revenue in Endometriosis Drugs Business (2021-2026)
- 12.10.4 Kissei Pharmaceutical Endometriosis Drugs Product Portfolio
- 12.10.5 Kissei Pharmaceutical Recent Developments
- 12.11 Evotec
- 12.11.1 Evotec Company Information
- 12.11.2 Evotec Business Overview
- 12.11.3 Evotec Revenue in Endometriosis Drugs Business (2021-2026)
- 12.11.4 Evotec Endometriosis Drugs Product Portfolio
- 12.11.5 Evotec Recent Developments
- 12.12 Debiopharm Group
- 12.12.1 Debiopharm Group Company Information
- 12.12.2 Debiopharm Group Business Overview
- 12.12.3 Debiopharm Group Revenue in Endometriosis Drugs Business (2021-2026)
- 12.12.4 Debiopharm Group Endometriosis Drugs Product Portfolio
- 12.12.5 Debiopharm Group Recent Developments
- 12.13 Astellas Pharma
- 12.13.1 Astellas Pharma Company Information
- 12.13.2 Astellas Pharma Business Overview
- 12.13.3 Astellas Pharma Revenue in Endometriosis Drugs Business (2021-2026)
- 12.13.4 Astellas Pharma Endometriosis Drugs Product Portfolio
- 12.13.5 Astellas Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst